Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report)’s stock price shot up 17.8% during mid-day trading on Tuesday . The company traded as high as $0.92 and last traded at $0.92. 99,128 shares traded hands during trading, an increase of 0% from the average session volume of 98,650 shares. The stock had previously closed at $0.78.
Chromocell Therapeutics Stock Performance
The business has a fifty day moving average of $0.65 and a 200-day moving average of $0.83.
Chromocell Therapeutics Company Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Featured Articles
- Five stocks we like better than Chromocell Therapeutics
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- What is a buyback in stocks? A comprehensive guide for investors
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- How to buy stock: A step-by-step guide for beginners
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
